Ann Neurol

1. CERONO G, Cree BAC, Hauser SL, Baranzini SE, et al
   Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence.
   Ann Neurol. 2025 Sep 8. doi: 10.1002/ana.78033.
   

   >> Share

   
   
2. ROY B, Chen J, Khani-Habibabadi F, McLaren N, et al
   A Distinct Immunological Signature in Late-Onset Myasthenia Gravis: Insights from an Exploratory Proteomics Study.
   Ann Neurol. 2025 Sep 6. doi: 10.1002/ana.78017.
   

   >> Share

   
   

   
   Curr Opin Immunol

3. CLEMENT TL, Cohen PL
   Can we cure lupus?
   Curr Opin Immunol. 2025;96:102640.
   

   >> Share

   
   
4. MAHARAJ S, Chang C
   Can juvenile idiopathic arthritis be cured?
   Curr Opin Immunol. 2025;96:102632.
   

   >> Share

   
   
5. SULLIVAN JK, Kwun A, Jorgensen TN
   Neuropsychiatric lupus: a myriad of symptoms requires a myriad of models.
   Curr Opin Immunol. 2025;96:102631.
   

   >> Share

   
   
6. FREE ME, Ciavatta DJ, Falk RJ
   Can we cure vasculitis?
   Curr Opin Immunol. 2025;96:102618.
   

   >> Share

   
   
7. CLAVARINO G, Vigne J, Meuleman MS, Amen A, et al
   Complement in systemic lupus erythematosus across time and space: from tolerance to tissue injury and from extracellular to intracellular functions.
   Curr Opin Immunol. 2025;97:102655.
   

   >> Share

   
   

   
   Diabetes Res Clin Pract

8. MADDALONI E, Zerunian M, Cardinale V, Zurru A, et al
   Liver disease in people with latent autoimmune diabetes in adults (LADA): A cross-sectional study using magnetic resonance elastography.
   Diabetes Res Clin Pract. 2025;229:112465.
   

   >> Share

   
   

   
   J Autoimmun

9. STASCHEIT F, Schulze D, Lehnerer S, Gerischer L, et al
   Calprotectin and neurofilament serum levels correlate with treatment response in myasthenia gravis under intensified therapy-A pilot study.
   J Autoimmun. 2025;157:103476.
   

   >> Share

   
   
10. KELLY S, Singh M, Russell A, Jackson KJL, et al
    Lymphoma driver mutations at the root of somatic evolution of nerve-damaging autoantibodies in myelin associated glycoprotein neuropathy.
    J Autoimmun. 2025;157:103474.
    

    >> Share

    
    

    
    J Clin Endocrinol Metab

11. VILLAGELIN D, Cooper DS
    Low Dose Methimazole in the Long-Term Management of Graves' Disease: Small doses, big benefits.
    J Clin Endocrinol Metab. 2025 Sep 10:dgaf503. doi: 10.1210.
    

    >> Share

    
    

    
    J Nephrol

12. PACKBIERS M, Hahm A, Riebeling T, Brasen JH, et al
    Treatment of recurrent IgA nephropathy after kidney transplantation with targeted-release budesonide - a case report.
    J Nephrol. 2025 Sep 12. doi: 10.1007/s40620-025-02405.
    

    >> Share

    
    
13. VISWANATHAN S, Seshadri J, Kurien AA, Palani Baskar HD, et al
    An observational study on mesangial C4d staining as a prognostic tool in IgA nephropathy.
    J Nephrol. 2025 Sep 9. doi: 10.1007/s40620-025-02410.
    

    >> Share

    
    

    
    J Neuroimmunol

14. XU XN, Luo WJ, Li HN, Li X, et al
    Treatment strategy for myasthenia gravis with GAD65-IgG associated neurological disorders: A case report.
    J Neuroimmunol. 2025;409:578741.
    

    >> Share

    
    

    
    J Neurol

15. ALONI R, Dror C, Barazani T, Kalron A, et al
    Wartime stress and relapse risk in people with multiple sclerosis: a prospective cohort study.
    J Neurol. 2025;272:619.
    

    >> Share

    
    
16. ZHU W, Chen Y, Tian C, Wang J, et al
    Factors associated with early response to efgartigimod in patients with generalized myasthenia gravis: a multicenter retrospective observational study.
    J Neurol. 2025;272:622.
    

    >> Share

    
    
17. YANG J, Li H, Zhang Y, Hu S, et al
    Effects of exercise on fatigue and quality of life in multiple sclerosis: a network meta-analysis and systematic review.
    J Neurol. 2025;272:621.
    

    >> Share

    
    
18. CHEN Y, Xie L, Cui H, Zhang Y, et al
    Autoimmune encephalitis with Anti-mGluR1 antibodies: a comprehensive review.
    J Neurol. 2025;272:623.
    

    >> Share

    
    
19. JU Y, Geng C, Guan H
    Initiation of tocilizumab within 24 hours in acute necrotizing encephalopathy is related to a good outcome: a systematic review.
    J Neurol. 2025;272:618.
    

    >> Share

    
    

    
    Mult Scler

20. TOUBASI A, Hett K, Xu J, Gheen C, et al
    Parasagittal dural space and arachnoid granulations morphology in pre-clinical and early clinical multiple sclerosis.
    Mult Scler. 2025 Sep 10:13524585251364720. doi: 10.1177/13524585251364720.
    

    >> Share

    
    
21. PONZANO M, Fedriga MM, Signori A, Bergamaschi R, et al
    Social determinants of health in multiple sclerosis in Italy: A scoping review.
    Mult Scler. 2025 Sep 10:13524585251353196. doi: 10.1177/13524585251353196.
    

    >> Share

    
    
22. ZHAO-FLEMING HH, Decker PA, Kosel ML, Drucker KL, et al
    Genomewide association study of a homogeneous multiple sclerosis cohort: Tumefactive demyelination.
    Mult Scler. 2025 Sep 8:13524585251371984. doi: 10.1177/13524585251371984.
    

    >> Share

    
    
23. GERNERT JA, Klein M, Schoberl F, Muller KJ, et al
    Severe course of tick-borne encephalitis (TBE) in a patient with relapsing multiple sclerosis (MS) treated with ocrelizumab.
    Mult Scler. 2025 Sep 11:13524585251369425. doi: 10.1177/13524585251369425.
    

    >> Share

    
    

    
    Neurol Clin Pract

24. LEECH J, Sauer BM, Baduashvili A, Corboy JR, et al
    Diagnostic Accuracy of Oligoclonal Bands for CNS Autoimmune Disorders in Acutely Ill Adults.
    Neurol Clin Pract. 2025;15:e200510.
    

    >> Share

    
    

    
    Neurologia (Engl Ed)

25. RUEDA-NIETO S, Mira-Escolano MP, Sanchez-Escamez A, Cayuela-Fuentes JM, et al
    Incidence and factors associated with disability and dependency in patients with Guillain-Barre syndrome in the Region of Murcia: Population study for the period 2009-2020.
    Neurologia (Engl Ed). 2025 Sep 4:S2173-5808(25)00088.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share